IMMB Stock Overview
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Immunotech Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0062 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -98.33% |
| 5 Year Change | 0% |
| Change since IPO | -99.97% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| IMMB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.7% | -3.7% |
| 1Y | n/a | -2.7% | 20.2% |
Return vs Industry: Insufficient data to determine how IMMB performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how IMMB performed against the US Market.
Price Volatility
| IMMB volatility | |
|---|---|
| IMMB Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IMMB has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine IMMB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | n/a | www.immunotechlab.com |
Immunotech Laboratories, Inc. develops and commercializes proprietary proteins for use in treating human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), hepatitis, and other immuno-related disorders. Its flagship compound is ITV-1 (immune therapeutic vaccine), a suspension of irreversible pepsin fraction that is used in the treatment of HIV/AIDS and Hepatitis C, as well as to modulate the immune system. The company is headquartered in Monrovia, California.
Immunotech Laboratories, Inc. Fundamentals Summary
| IMMB fundamental statistics | |
|---|---|
| Market cap | US$57.50k |
| Earnings (TTM) | -US$977.57k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs IMMB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMMB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$977.57k |
| Earnings | -US$977.57k |
Last Reported Earnings
Dec 31, 2009
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did IMMB perform over the long term?
See historical performance and comparison